NCEL SEC Filing News — NewcelX Ltd.

Latest SEC filings for NewcelX Ltd. (NCEL) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-04-29.

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small…
Sector: Healthcare Industry: Biotechnology Market Cap: $14.4M CIK: 1783036
2
Total Filings
2
Bullish Classifications
0
Bearish Classifications
2
Insider Transactions
0
Material Events (8-K)
0
Periodic Reports
Rule-based classifications for NCEL currently lean bullish. Of the 2 displayed SEC filing records, 2 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 2 insider transactions (Form 4) in this period.
Insider Transactions 2 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 2 filings in this group are Form 4s for NewcelX Ltd.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 2 insider filings shown, the breakdown is 2 open-market purchase. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market purchase ×2
The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Form 4 Open-market purchase Insider Buying 2026-04-29

NCEL insider Samuel Olivier (Director) bought 81,818 shares (~$225.0K)

Samuel Olivier, listed as Director at NewcelX Ltd., reported an open-market purchase of 81,818 NCEL shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 81,818 $2.75 $225.0K
P Open-market purchase derivative · Warrant (right to buy) 114,545 — —
Filing: Form 4 (Insider Transaction) Insider: Samuel Olivier (Director) Shares: 81,818 Est. Value: $225.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-04-29

NCEL insider Revel Michel (Director, CSO and Director, 10% Owner) bought 54,545 shares (~$150.0K)

Revel Michel, listed as Director, CSO and Director, 10% Owner at NewcelX Ltd., reported an open-market purchase of 54,545 NCEL shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 54,545 $2.75 $150.0K
P Open-market purchase derivative · Warrant (right to buy) 76,363 — —
Filing: Form 4 (Insider Transaction) Insider: Revel Michel (Director, CSO and Director, 10% Owner) Shares: 54,545 Est. Value: $150.0K
View on SEC EDGAR → Open Filing Document →

How we classify NewcelX Ltd.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on NCEL. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — NCEL SEC Filings

More Tools for NCEL

NCEL Full Stock Analysis NCEL Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper NCEL analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the NCEL stock analysis page.

NCEL Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer